Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism

German Kamalov,1 Robert A. Ahokas,2 Wenyuan Zhao,1 Atta U. Shahbaz,1 Syamal K. Bhattacharya,1 Yao Sun,1 Ivan C. Gerling,3 and Karl T. Weber1
1Division of Cardiovascular Diseases, 2Department of Obstetrics and Gynecology, and 3Division of Endocrinology, University of Tennessee Health Science Center, Memphis, Tennessee
Submitted 2 July 2009; accepted in final form 9 November 2009

Kamalov G, Ahokas RA, Zhao W, Shahbaz AU, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol 298: H385–H394, 2010. First published November 13, 2009; doi:10.1152/ajpheart.00593.2009.—Intracellular Ca2+ overload, coupled to induction of oxidative stress, is present at 4-wk aldosterone/salt treatment (ALDOST). This prooxidant reaction in cardiac myocytes and mitochondria accounts for necrotic cell death and subsequent myocardial scarring. It is intrinsically linked to increased intracellular zinc concentration ([Zn2+]i) serving as an antioxidant. Herein, we addressed the temporal responses in coupled Ca2+ and Zn2+ dyshomeostasis, reflecting the prooxidant-antioxidant equilibrium, by examining preclinical (week 1) and pathological (week 4) stages of ALDOST to determine whether endogenous antioxidant defenses would be ultimately overwhelmed to account for this delay in cardiac remodeling. We compared responses in cardiomyocyte free [Ca2+]i and [Zn2+]i, and mitochondrial total [Ca2+]im and [Zn2+]im, together with biomarkers of oxidative stress and antioxidant defenses, during 1- and 4-wk ALDOST. At week 1 and compared with controls, we found: 1) elevations in [Ca2+]i, and [Ca2+]im were coupled with [Zn2+]i, and [Zn2+]im; 2) increased mitochondrial H2O2 production, cardiomyocyte xanthine oxidase activity, and cardiac and mitochondrial 8-isoprostane levels, counterbalanced by increased activity of antioxidant proteins, enzymes, and the nonenzymatic antioxidants that can be considered as cumulative antioxidant capacity; some of these enzymes and proteins (e.g., metallothionein-1, Cu/Zn-superoxide dismutase) are regulated by metal-responsive transcription factor-1; and 3) although these augmented antioxidant defenses were sustained at week 4, they fell short in combating the persistent intracellular Ca2+ overload and marked rise in cardiac tissue 8-isoprostane and mitochondrial transition pore opening. Thus a coupled Ca2+ and Zn2+ dyshomeostasis occurs early during ALDOST in cardiac myocytes and mitochondria that regulate redox equilibrium until week 4 when ongoing intracellular Ca2+ overload and prooxidants overwhelm antioxidant defenses.

aldosterone; oxidative stress; antioxidants

MORE THAN FOUR DECADES ago, Fleckenstein (25) originally proposed that intracellular Ca2+ overload of cardiomyocytes and their mitochondria, coupled with a loss of high-energy- rich phosphates, account for irreversible structural damage to these organelles and subsequent cellular necrosis. They validated their hypothesis using a single dose of a catecholamine to induce an acute Ca2+ overload and vera- pamil, a Ca2+ antagonist later proved to be a Ca2+ blocker, to prevent ensuing cardiac pathology. Nakayama et al. (56) have reevaluated Fleckenstein’s hypothesis of intracellular Ca2+ overload-induced cardiomyocyte necrosis as a primary mediator of heart failure. Using transgenic mice with overexpressed sarcolemmal L-type Ca2+ channels, they found progressive necrotic death of these cells, which led to ventricular dysfunction and shortened survival of these rodents. Iso- proterenol, a synthetic catecholamine, accelerated these adverse events, whereas an L-type Ca2+ channel blocker or β1-adrenergic receptor antagonist prevented them altogether. We demonstrated the pathogenic roles of excessive intracellular Ca2+ accumulation (EICA; Ref. 10) as well as the cardioprotective properties of diltiazem (12) and parathyroidectomy (57) in the cardiomyopathy found in the Syrian hamster with muscular dystrophy. Subsequent studies with ischemia-reperfusion (I/R) injury would identify the induction of oxidative stress that accompanies acute EICA in leading to cardiomyocyte necrosis (38). The necrotic cell death pathway that occurs in cardiomyocytes in response to catecholamines or I/R injury is now recognized to initiate in mitochondria and is mediated via the opening of the mitochondrial permeability transition pore (mPTP), which is regulated by cyclophilin D and for which inhibition is cardioprotective (18, 38, 42, 56).

Using 4-wk aldosterone/salt treatment (ALDOST) in rats to simulate chronic, inappropriate (relative to dietary Na+), homeostatic activation of the renin-angiotensin-aldosterone system that accompanies reduced renal perfusion in patients with heart failure, we identified parathyroid hormone (PTH)-mediated subacute EICA in cardiomyocytes and mitochondria of the normal heart as associated with the induction of oxidative stress at these cellular and subcellular sites together with cardiomyocyte necrosis and myocardial scarring (19, 66, 69). Cotreatment with the following prevents this prooxidant state: spironolactone, an aldosterone receptor antagonist, attenuates the heightened urinary and fecal excretion of Ca2+ and consequent appearance of ionized hypocalcemia to prevent secondary hyperparathyroidism (SHPT; Ref. 19); a dietary Ca2+ supplement, together with vitamin D, to prevent hypocalcemia and SHPT (33); parathyroidectomy (69); a calcimimetic that resets the Ca2+-sensing threshold of the parathyroid glands to prevent SHPT (60); amiodarone, an L-type Ca2+ channel blocker (2); or an antioxidant (66). Thus PTH-mediated intracellular Ca2+ overload and the induction of oxidative stress are integral pathophysiological responses that account for adverse cardiac remodeling during chronic aldosteronism. Several additional lines of investigation demonstrate the cardiac fibrosis seen with ALDOST is not related to aldosterone per se. First, fibrosis does not appear when rats are treated with aldosterone together with dietary Na+ deprivation (14). Sec-
ond, fibrosis is not found in transgenic mice with a cardiосpe-
ific overexpression of aldosterone synthase that accounts for
increased aldosterone levels in the myocardium (28). Third,
evations in plasma prorenin and aldosterone found in
Cyp1a1-Ren2 transgenic rats are not accompanied by cardiac
fibrosis (58a). Collectively, these studies further underscore the
importance of inappropriate (relative to dietary Na+ intake)
evations in plasma aldosterone in predisposing the myocar-
dium to reparative fibrosis through PTH-mediated intracellular
Ca2+ overloading and induction of oxidative stress that regu-
late mPTP opening with ensuing necrotic cell death. As we
(19) reviewed previously, urinary Ca2+ excretion occurs in the
distal segment of the nephron and is dietary Na+ -dependent.
Hypercalciuria accompanies the short-term treatment of hu-
mans or animals with a mineralocorticoid and dietary Na+ (17,
29, 50, 64, 75). Increased dietary Na+ intake is calciric
with enhanced excretory Ca2+ losses, accentuated by prior
uninephrectomy, leading to plasma-ionized hypocalcemia and
SHPT.

It is noteworthy we found that subacute intracellular Ca2+
overloading associated with ALDOST to be accompanied by a
concomitant antioxidant response invoked by the intrinsic
coupling of Ca2+ and Zn2+ dyshomeostasis, which includes
Zn2+ entry, via L-type Ca2+ channels to a lesser extent and
primarily by the upregulated expression of Zn2+ transporters
(26, 44). Increased cytosolic free Zn2+ serves to activate its
sensor, the metal-responsive transcription factor (MTF)-1, to
regulate the expression of endogenous antioxidant defenses
including metallothionein (MT)-1, Cu/Zn-SOD, and glutathi-
one synthase (5, 44). In this context, we also found the cotreatment of ALDOST with a ZnSO4 supplement to prevent
cardiomyocyte necrosis and scarring (26). Thus the pathophys-
iological balance between prooxidants and antioxidants ap-
pears to dictate the fate of cardiomyocytes during chronic
aldosteronism, although its mechanism of action distinctly
differs from the acute EICA seen with catecholamines or I/R
injury, where upregulated antioxidant defenses are immedi-
ately overwhelmed.

To gain further mechanistic insights into Ca2+ and Zn2+
 dyshomeostasis in cardiac myocytes and mitochondria and the
relatable interplay between oxidative stress and antioxidant
defenses before and during the appearance of cardiac pathol-
ogy, weeks 1 and 4 of ALDOST, respectively, the framework
of the present study was designed. Herein, we sought to
determine the temporal responses in prooxidants [intracellular
calcium concentration ([Ca2+]i)] and mitochondrial calcium concen-
tration ([Ca2+]m)] and antioxidants ([Zn2+]i), and [Zn2+]m) relative
to the redox state of cardiac myocytes and mitochondria present
at week 1 ALDOST, the preclinical stage, and at week 4, the
pathological stage, coincident with myocardial scarring, a foot-
print of prior cardiomyocyte necrosis that appears throughout the
right and left heart independent of hemodynamic factors
(65). By targeting this time course, we explored whether the rise in intracellular Ca2+ and Zn2+ occurred early and was
accompanied by a persistent induction of oxidative stress and
upregulation of antioxidant defenses, which was then over-
whelmed by the increased rate of reactive oxygen species
(ROS) and nitrogen species generation. Alternatively, there
could be a putative progressive rise in these intracellular
cations that culminate in an overall prooxidant-antioxidant
imbalance at week 4. To test these hypotheses, we examined
cardiac myocytes and mitochondria harvested from hearts
obtained at weeks 1 and 4 ALDOST and monitored: [Ca2+]i
and [Zn2+]i, [Ca2+]m and [Zn2+]m, together with biomarkers of
oxidative stress and antioxidant defenses and propensity for
mPTP opening. Unoperated, untreated, age-/sex-matched rats
served as controls.

METHODS

Animal Model

Eight-week-old male Sprague-Dawley rats were used throughout
this series of experiments approved by our institution’s Animal Care
and Use Committee. Unoperated, untreated age-/sex-matched rats
served as controls. As reported previously and following uninep-
rectomy, an osmotic minipump containing aldosterone was implanted
subcutaneously. It releases aldosterone (0.75 μg/h) to raise circulating
aldosterone levels to those commonly found in human congestive
heart failure (CHF) and suppresses plasma renin activity and circu-
ulating levels of angiotensin II. Drinking water was fortified with 1% NaCl and 0.4% KCl to prevent hypokalemia. A detailed accounting of
this ALDOST model, including various controls (e.g., uninepre-
rectomy, aldosterone, or 1% NaCl treatment alone) has been reported
elsewhere (44, 72). We (13, 66) also have extensively described the
cardiac pathology that first appears at week 4 ALDOST, and, there-
fore, it is not repeated herein. In brief, the adverse myocardial
structural remodeling involving the right and left heart that accompa-
nies ALDOST is not a consequence of hemodynamic factors or
daldosterone per se (72). Instead, cardiomyocyte necrosis with resultant
reparative fibrosis is the result of intracellular Ca2+ overloading and
oxidative stress mediated by SHPT (reviewed in Ref. 45).

Isolation of Cardiomyocytes and Mitochondria

Cardiomyocytes were harvested by retrograde collagenase perfu-
sion of the crystalloid perfused heart, and mitochondria were isolated
by differential centrifugation of whole heart homogenates. The purity
of mitochondrial preparation was assessed by flow cytometry and
mitochondrial-specific dye MitoTracker Red (Invitrogen, Eugene,
OR) as we (26) previously reported. Given the paucity of mitochon-
drial population density in endothelial and smooth muscle cells and
fibroblasts, we speculate that overall these cells may not be a likely
source of contamination. Membrane integrity of isolated mitochondria
was assessed using a commercially available kit per the manufacturer’s
instructions (Invitrogen). Mitochondria were stained with cationic dye
JC-1 followed by flow cytometry with and without mitochondrial
membrane potential disruptor CCCP.

Cardiomyocyte Cytosolic Free [Ca2+]i and [Zn2+]i.

Cytosolic free Ca2+ concentration ([Ca2+]i) was measured rati-
ometrically using the Ca2+-specific fluorophore Fura-2 (Invitrogen) as
we (2, 3) have previously reported. Cytosolic free Zn2+ concentration ([Zn2+]i) of viable cardiomyocytes was measured by 2-color flow
cytometry (BD FACS Calibur; Becton Dickinson, Franklin Lakes, NJ)
using zinc-specific dye FluoZin-3 (Invitrogen), and propidium iodide
(Sigma, St. Louis, MO) was used for detection of the nonviable cells
as we (26) reported previously.

Mitochondrial Total [Ca2+]m and [Zn2+]m

Total calcium and zinc concentration ([Ca2+]m) and [Zn2+]m) in
cardiac mitochondria were determined by flame atomic spectroscopy
and expressed as nanograms per milligram mitochondrial protein as
previously described (11).

mPTP Opening

mPTP opening was determined by Ca2+-induced swelling of iso-
lated cardiac mitochondria according to Baines et al. (7). As reported
by these investigators, only the 200 μM Ca\(^{2+}\) concentration provided a reproducible and stable decrease in mitochondrial optical density. This decrease in optical density was completely prevented after preincubation with 30 nM cyclosporine A (CsA), thus confirming the specificity of the mPTP opening assay.

**Oxidative Stress: Prooxidants**

**8-Isoprostane.** Mitochondrial and cardiac tissue total 8-isoprostane (free and esterified) levels were measured using a competitive enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s protocol and as reported by us previously (26).

**Mitochondrial H\(_2\)O\(_2\) production.** Mitochondrial ROS production is potentiated by a rise in intramitochondrial [Ca\(^{2+}\)], partially through stimulation of Krebs cycle enzymes with increased flux of electrons to the respiratory chain. To measure the release of H\(_2\)O\(_2\) from isolated cardiac mitochondria stimulated by succinate, the Amplex Red (In-vitrogen) protocol of Mohanty et al. (54) was used with minor modifications as previously reported by us (44).

**Xanthine oxidase activity.** Xanthine oxidase (XO) is another well-established source of ROS in cardiac myocytes. Xanthine dehydrogenase/oxidase catalyzes the final two steps of purine catabolism with formation of the end product, uric acid, from hypoxanthine and xanthine. The mammalian enzyme is synthesized as a dehydrogenase (XDH) that uses NAD\(^{+}\) as the electron acceptor, but it can also be converted into an oxidase (XO). The oxidase form consumes molecular oxygen as the electron acceptor and releases substantial amounts of superoxide anions (O\(_2^{•−}\)) and hydrogen peroxide (H\(_2\)O\(_2\)) under certain conditions with redox stress (e.g., I/R injury). Reversible conversion into XO may also take place readily through sulfhydryl group oxidation (21). However, irreversible conversion occurs through proteolytic cleavage and is shown to be regulated by intracellular Ca\(^{2+}\) (51, 52). XO activity was determined in cardiomyocyte extracts using an Amplex Red kit (Invitrogen). Briefly, 50 μl of cell homogenate was incubated in a microplate with 50 μl of working solution containing 100 μM Amplex Red, 0.4 U/ml horseradish peroxidase, and 200 μM xanthine. Samples were incubated at 37°C for 30 min, and absorbance was measured at 570 nm. To account for background correction, absorbance was also determined before sample incubation and subtracted from the final absorbance. XO activity was calculated using the standard curve and expressed in milliunits per milligram protein.

**Oxidative Stress: Antioxidants**

**Glutathione peroxidase activity.** Glutathione peroxidase (GSHPx) activity and GSSG were measured in cardiac myocytes and isolated mitochondria as previously reported by us (44).

**Cu/Zn-SOD and MnSOD activity.** Total Cu/Zn- and MnSOD activities in mitochondria and cardiac myocytes were measured spectrophotometrically as previously reported by us (44).

**GSSG.** GSSG in cardiomyocytes and isolated mitochondria were measured as reported previously by us (44).

**Total antioxidant capacity.** Total antioxidant capacity (TAC) of cardiac myocytes and isolated mitochondria was measured using a commercially available reagent kit (Cayman Chemical). The TAC provides more relevant biological information compared with that obtained by the measurement of individual components, as it represents the cumulative contributions from all antioxidants present in tissue, such as proteins (e.g., albumin, ceruloplasmin) and small molecules, including ascorbic acid, α-tocopherol, β-carotene, GSSG, uric acid, and bilirubin. This assay relies on the capacity of the sample-derived antioxidants to inhibit the oxidation of 2,2′-azino-di-(3-ethylbenzthiazoline sulfonate) (ABTS) to ABTS\(^{+}\) by metmyoglobin. The capacity of the antioxidants present in the sample to prevent ABTS oxidation is compared with that of Trolox, a water-soluble tocopherol analog, and is quantified as molar Trolox equivalents per milligram protein.

**Gene Microarray Analysis**

Myocardial tissue was harvested from untreated, age-/sex-matched controls after 1 and 4 wk of ALDOST. The tissue was immersed and stored in RNA preservation agent (RNALater), and then a TRI reagent (TRIzol) was added, the tissue was homogenized, and RNA was extracted as previously described (30, 31). Gene expression analysis was carried out using Affymetrix expression arrays to evaluate the changes in mRNA expression by comparing left ventricular tissue obtained from controls with 1- and 4-wk ALDOST-treated rats. We analyzed 6 independent samples from each of the 3 groups on the MOE230.2 expression array (Affymetrix), which revealed expression levels of >31,000 probe sets. Affymetrix gene expression analysis and data normalization have been extensively described by us previously (30, 31). Nine genes (from the 31,000 probe sets) were selected for analysis based on being antioxidant enzymes present on the expression array and having significant expression levels in the samples.

**Immunoblotting**

For immunoblotting, cardiomyocytes were lysed with SDS-urea buffer (40 mM HEPES, 4 M urea, 1% SDS, 75 mM Tris, pH 7.4). From each sample, 20 μg of total protein was separated on 10% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane according to standard procedures. The nonspecific protein binding in membrane was blocked by 5% nonfat milk in TBST (0.05% Tween 20) for 1 h. Incubation with the primary antibodies to rabbit polyclonal anti-MTP-1 (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA) and mouse monoclonal anti-GAPDH (1:10,000; Chemicon, Temecula, CA) were carried out overnight at 4°C. Immunodetection was achieved using the horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (1:10,000; Sigma), and bands were visualized with the enhanced chemiluminescence (ECL) system. To quantitate protein expression, optical density of the protein bands was measured using ImageJ software [National Institutes of Health (NIH), Bethesda, MD]. Protein loading was normalized using GAPDH as housekeeping protein. Immunoblotting data were presented as fold change relative to control cardiomyocytes.

**Statistical Analysis**

Group data are presented as means ± SE. Data were analyzed by the Mann-Whitney rank sum test using SigmaStat statistical software (version 2.0; Systat Software, Point Richmond, CA). Expression levels of the nine antioxidant genes in ALDOST rats from the expression arrays were normalized to the mean of their expression in control samples and presented as fold change. We analyzed fold change data by a one-way ANOVA. Significant differences between individual group means were assigned when P values were <0.05.

**RESULTS**

**Coupled Ca\(^{2+}\) and Zn\(^{2+}\) Dyshomeostasis**

**Cardiomyocytes.** Compared with controls (29 ± 4 nM), cytosolic free [Ca\(^{2+}\)]\(_{i}\) in cardiomyocytes was already increased (P < 0.05) by week 1 ALDOST (70 ± 5 nM) and remained elevated (P < 0.05) at week 4 (80 ± 5 nM). This early and persistent Ca\(^{2+}\) overloading of cardiomyocytes was also accompanied by a persistent increase of [Zn\(^{2+}\)]\(_{i}\) in these cells (Fig. 1). Compared with controls (0.76 ± 0.12 nM), cytosolic [Zn\(^{2+}\)]\(_{i}\) was significantly increased (P < 0.05) by week 1 (1.77 ± 0.09 nM) and week 4 (1.64 ± 0.08 nM) ALDOST.

**Mitochondria.** As seen in Fig. 2, the total Ca\(^{2+}\) concentration in mitochondria [Ca\(^{2+}\)]\(_{m}\) harvested from control hearts was 47.9 ± 4.9 ng/mg mitochondrial protein, whereas that at weeks 1 and 4 of ALDOST (89.5 ± 5.7 and 103.4 ± 10.4
ng/mg mitochondrial protein, respectively) were elevated significantly \((P < 0.05)\) at both week 1 and 4 ALDOST compared with controls (Table 1).

Cardiac 8-isoprostane. Oxidative damage with lipid peroxidation in the myocardium is reflected by increased 8-isoprostane tissue levels. At week 1 ALDOST, the 8-isoprostane level \((46.4 \pm 9.5 \text{ pmol/mg protein})\) was increased \((P < 0.05)\) compared with control hearts \((32.8 \pm 5.8)\), although there was no morphological evidence of myocardial scarring at this preclinical stage. Coincident with the appearance of scarring, a marker of necrosis, at week 4 ALDOST as reported previously \((66)\), cardiac tissue 8-isoprostane levels \((341.8 \pm 50.1 \text{ pmol/mg protein})\) were markedly increased above the control levels \((P < 0.01)\) as well as at week 1 of ALDOST \((P < 0.01)\).

Antioxidant Defenses

The induction of oxidative stress seen in the heart at weeks 1 and 4 ALDOST, contemporaneous with intracellular \(\text{Ca}^{2+}\) overloading, was accompanied by the upregulated transcription \((P < 0.05)\) of multiple antioxidant enzymes. MTF-1, the intracellular \(\text{Zn}^{2+}\) sensor, is activated by increased cytosolic \([\text{Zn}^{2+}]_i\) in ALDOST (Fig. 1) compared with controls \((1.0 \pm 0.4)\). The MTF-1 protein level was increased \((1.9 \pm 0.2)\) at week 1 and \((2.7 \pm 0.2)\) at week 4 ALDOST. Activated MTF-1 then translocates to the nucleus, where it induces the transcription of several antioxidant genes, such as MT-1 and glutathione synthase (Table 1). These values represent the fold increase relative to controls with the assigned value of 1.00. The rise in MT-1 protein seen at weeks 1 and 4 ALDOST was reported by us previously \((68)\).

Similarly, the mRNA expression for xanthine dehydrogenase was also increased \((P < 0.05)\) at both week 1 and 4 ALDOST compared with controls (Table 1).

Biomarkers of Oxidative Stress

In cardiomyocytes, two major sources of ROS are mitochondria and cytosolic XO.

Mitochondrial production of \(\text{H}_2\text{O}_2\). As seen in the top of Fig. 3, succinate-stimulated mitochondrial production of \(\text{H}_2\text{O}_2\) in controls \((91.0 \pm 13.4 \text{ pmol/mg mitochondrial protein}^{-1}\text{min}^{-1})\) was already increased \((P < 0.05)\) at week 1 ALDOST \((118.3 \pm 8.4)\) and rose further \((P < 0.05)\) at week 4 \((157.6 \pm 13.2)\), implicating that induction of oxidative stress ensued by week 1 and was further exacerbated by week 4.

Mitochondrial 8-isoprostane. Mitochondrial 8-isoprostane levels (Fig. 3, bottom) were also increased \((P < 0.05)\) during ALDOST. A marked temporal rise in mitochondrial 8-isoprostane was seen at week 1 \((878.7 \pm 95.7 \text{ pmol/mg mitochondrial protein})\), and it remained significantly elevated at week 4 \((323.5 \pm 26.8)\) compared with controls \((124.6 \pm 9.3)\).

XO activity. XO activity in cardiomyocytes (Fig. 4) harvested from hearts at week 1 \((2.08 \pm 0.51 \text{ mU/mg protein})\) and week 4 \((2.93 \pm 0.58)\) ALDOST was significantly increased \((P < 0.05)\) compared with that found in controls \((1.48 \pm 0.14)\).
respectively, vs. 0.19 

2.6 and 34.8

increased (Cu/Zn SOD activity in cardiomyocytes (Fig. 5, expression did not change with ALDOST (Table 1). However, with controls (3.64 

likewise, the GSHPx activity in cardiac mitochondria at 1 (5.95 

showed a 10 –20% increase in GSHPx mRNA at week 1 compared with controls (6.04 

compared with controls (6.04 

respectively, compared with controls (5.10 

progressive rise in mitochondrial 8-isoprostane levels found at week 1 compared with week 4, thus providing experimental evidence of the imbalance between pro- and antioxidant defenses during ALDOST.

mPTP opening. Mitochondrial Ca\(^{2+}\) overloading commensurate with the high cardiomyocyte cytosolic [Ca\(^{2+}\)], levels may initiate the opening of a nonspecific pore in the inner mitochondrial membrane, the mPTP. This Ca\(^{2+}\)-dependent formation and regulation of the mPTP opening is followed by an abrupt increase in the permeability of solutes (<1,500 Da mol mass) that are normally impermeable to the mitochondrial inner membrane, causing osmotic swelling and rupture of the outer membrane with concomitant loss of mitochondrial proteins. We detected (Fig. 6) a marked increase in the Ca\(^{2+}\)-induced opening of mPTP in cardiac mitochondria isolated from ALDOST rats (ΔA\(_{520}\) 107.4 ± 9.3 at week 4 ALDOST vs. 68.6 ± 9.5 in controls; \(P < 0.05\)).

DISCUSSION

The administration of a catecholamine or I/R injury each lead to acute Ca\(^{2+}\) overloading in cardiac myocytes and mitochondria, with a concomitant loss of high-energy-rich phosphates that account for irreversible structural damage of these organelles and subsequent necrosis of energy-starved cardiomyocytes. Based on monoclonal antmyosin antibody labeling studies, cardiomyocyte necrosis is evident within hours of

GSHPx expression and activity. Analysis of microarray data showed a 10–20% increase in GSHPx mRNA at weeks 1 and 4 ALDOST, respectively (Table 1). GSHPx activity (Fig. 5, top) was consistently elevated (\(P < 0.05\)) in cardiomyocytes at week 1 (0.23 ± 0.02) and week 4 (0.25 ± 0.01) ALDOST, respectively, vs. 0.19 ± 0.01 mU/mg protein in controls. Likewise, the GSHPx activity in cardiac mitochondria at week 1 (5.95 ± 0.36) and week 4 (5.10 ± 0.34) ALDOST, respectively, were also significantly elevated (\(P < 0.05\)) compared with controls (3.64 ± 0.25 mU/mg mitochondrial protein).

Cu/Zn-SOD and MnSOD activities. Cu/Zn SOD mRNA expression did not change with ALDOST (Table 1). However, Cu/Zn SOD activity in cardiomyocytes (Fig. 5, bottom) was increased (\(P < 0.05\)) during weeks 1 and 4 ALDOST (28.7 ± 2.6 and 34.8 ± 3.9), respectively, compared with controls (22.9 ± 1.1 U/mg protein).

On the other hand, activity of mitochondrial MnSOD did not change significantly with ALDOST (data not shown).

Glutathione. Levels of GSSG in cardiac myocytes were elevated at weeks 1 and 4 ALDOST (1.86 ± 0.34 and 2.04 ± 0.32 nmol/mg protein, respectively, vs. 1.57 ± 0.12 in controls), reflecting a persistent increase in oxidative stress. A compensatory increase in reduced and total glutathione also occurred at week 1 (10.1 ± 0.7) and week 4 (9.6 ± 1.02), respectively, compared with controls (6.04 ± 0.4 nmol/mg protein). However, the GSH-to-GSSG ratio did not change significantly (data not shown).

The mRNA levels for enzymes glutathione synthase and thioredoxin reductase were also elevated during ALDOST compared with controls (Table 1). Furthermore, a significant upregulation of glutathione S-transferase enzymes (GSTs) was seen with ALDOST (Table 1). GSTs catalyze the conjugation of GSSG, via the sulfhydryl group, to electrophilic centers on a wide variety of substrates. This activity is useful in the detoxification of endogenous compounds such as peroxidized lipids.

TAC. TAC embodies nonenzymatic low-molecular weight antioxidants and vitamins (A, C, and E). In cardiac myocytes, TAC was increased at week 1 ALDOST, however, no further increase was observed at week 4 despite continuing presence of oxidative stress suggesting that antioxidant reserves were overwhelmed (3.96 ± 0.6 and 3.15 ± 0.46 at weeks 1 and 4, respectively, vs. 1.87 ± 0.26 Trolox U/mg protein in controls). In contrast, mitochondrial TAC initially fell following 1-wk ALDOST but later returned to the control levels (control, 14.2 ± 2.06 vs. 9.9 ± 2.2 and 16.01 ± 1.6 at weeks 1 and 4 ALDOST, respectively). These data putatively implicate a disproportionate rise in mitochondrial 8-isoprostane levels observed at weeks 1 and 4 ALDOST but later returned to control levels (control, 0.32 nmol/mg protein, respectively, vs. 1.57 ± 0.12 in controls).

Fig. 3. Mitochondrial H\(_2\)O\(_2\) production and 8-isoprostane levels in organelles harvested from control hearts as well as with 1- and 4-wk ALDOST. *\(P < 0.05\) vs. controls.

Fig. 4. Cardiomyocyte xanthine oxidase (XO) activity measured in cells harvested from control hearts as well as at weeks 1 and 4 ALDOST. *\(P < 0.05\) vs. controls.
isoproterenol administration (9, 32). Herein, we exploited our rat model of chronic ALDOST where intracellular Ca²⁺ overloading of cardiac myocytes and mitochondria was known to be present at week 4 coincident with delayed myocardial necrosis and scarring (26, 66). The subacute intracellular Ca²⁺ overloading in this model is intrinsically coupled to increased intracellular Zn²⁺, where Ca²⁺ and Zn²⁺ entry serve as prooxidant and antioxidant, respectively (44). The first objective of our study therefore was to determine the temporal responses in the coupled Ca²⁺ and Zn²⁺ dyshomeostasis that occur in these cells and organelles before the appearance of cardiac pathology (week 1) and during the ensuing pathological stage (week 4), together with their relevant biomarkers of oxidative stress and pathophysiological responses in antioxidant defenses.

We found that cytosolic free [Ca²⁺]i and mitochondrial [Ca²⁺]m in cardiomyocytes were already increased severalfold above the control values at week 1 of ALDOST and remained significantly elevated at week 4. As we have previously reported, the rise in [Ca²⁺]i occurs via l-type Ca²⁺ channels and is PTH-mediated; and ALDOST is indirectly responsible for these responses as it promotes SHPT via increased excretory Ca²⁺ losses with the contemporaneous appearance of ionized hypocalcemia (19, 44, 60, 69). The sustained elevation in [Ca²⁺]m implicates the activation of a Na⁺-dependent mitochondrial uniporter for which the primary function is to sequester Ca²⁺ under pathological stimuli (37). Michels and coworkers (53) have recently identified hitherto unknown Ca²⁺ selective channels in mitochondria obtained from nonfailing and failing human hearts, and their activity was significantly reduced in failing hearts due to impaired Ca²⁺ uptake. Relative to Ca²⁺ efflux, Smogorzewski et al. (62) found Ca²⁺-ATPase-mediated extrusion of Ca²⁺ from cardiomyocytes to be reduced with SHPT, which further contributes to intracellular Ca²⁺ overloading. Mitochondrial Ca²⁺ extrusion is mediated by Na⁺-Ca²⁺ exchanger located in the inner membrane (35). It is presently uncertain whether the function of this exchanger is altered during ALDOST, although the role of mitochondrial Na⁺-Ca²⁺ exchanger in the pathophysiological expression of dystrophic cardiomyopathy has been previously studied by one

---

**Table 1. mRNA expression of antioxidant enzymes**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>ALDOST, 1 wk</th>
<th>ALDOST, 4 wk</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xanthine dehydrogenase</td>
<td>1.0±0.0</td>
<td>1.6±0.1</td>
<td>1.3±0.1</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>MT-1, mRNA</td>
<td>1.0±0.2</td>
<td>1.5±0.4</td>
<td>2.4±0.2</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>Glutathione synthase</td>
<td>1.0±0.1</td>
<td>1.5±0.1</td>
<td>1.5±0.0</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>Glutathione peroxidase</td>
<td>1.0±0.0</td>
<td>1.2±0.0</td>
<td>1.2±0.0</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>Glutathione S-transferase, α-type</td>
<td>1.0±0.1</td>
<td>1.4±0.2</td>
<td>1.4±0.1</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>Glutathione S-transferase, µ-type 2</td>
<td>1.0±0.0</td>
<td>1.5±0.0</td>
<td>1.6±0.1</td>
<td>P &lt; 0.01</td>
</tr>
<tr>
<td>Thioredoxin reductase 1</td>
<td>1.0±0.1</td>
<td>1.5±0.1</td>
<td>1.3±0.1</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>Cu/Zn-SOD</td>
<td>1.0±0.0</td>
<td>1.0±0.1</td>
<td>1.0±0.0</td>
<td>NS</td>
</tr>
<tr>
<td>MnSOD</td>
<td>1.0±0.0</td>
<td>0.9±0.1</td>
<td>0.8±0.1</td>
<td>NS</td>
</tr>
</tbody>
</table>

Aldosterone/salt treatment (ALDOST) 1- and 4-wk data are expressed as fold changes (means ± SE) relative to the normal controls, which were assigned a value of 1.00 ± SE. P values compare control vs. 4-wk ALDOST. MT-1, metallothionein-1; NS, not significant.

---

**Fig. 5.** Cardiomyocyte glutathione peroxidase (GSHPx) activity and Cu/Zn-SOD activity in cells harvested from control hearts as well as at weeks 1 and 4 ALDOST. *P < 0.05.

**Fig. 6.** Mitochondrial swelling was induced by 200 μmol/l CaCl₂. The decrease in changes in adsorption at 560 nm wavelength per minute (A560/min) rate of absorbance was plotted against time (minutes). Four-week ALDOST markedly increased mitochondrial transition pore opening compared with control. Mitochondrial transition pore opening was completely prevented by cyclosporine A (CsA).

---

"CALCIUM AND ZINC DYSHOMEOSTASIS"
of us (S. K. Bhattacharya). The early and persistent Ca\(^{2+}\) overload of cardiac myocytes and their mitochondria was accompanied by a severalfold rise in [Zn\(^{2+}\)]\(_{i}\) and [Zn\(^{2+}\)]\(_{m}\) at weeks 1 and 4 ALDOST, which we have shown to be associated with the increase expression of cardiomyocyte Zn\(^{2+}\) transporters induced by oxidative stress and preventable by cotreatment with spironolactone or amldipine (44). Mechanisms of cardiac mitochondrial Zn\(^{2+}\) uptake remain to be fully elucidated. However, we speculate a transporter associated with the inner membrane would putatively involve a direct exchange between the Zn\(^{2+}\)-bound metallothionein chaperone complex with the transporter (22, 36).

At week 1 ALDOST, the Ca\(^{2+}\) overload of cardiac myocytes and mitochondria was accompanied by a significant rise in cardiomyocyte XO activity and mitochondrial H\(_{2}\)O\(_{2}\) production together with an elevation in cardiac tissue 8-isoprostane level. However, this amplified prooxidant profile was also accompanied by simultaneous upregulated transcription of multiple antioxidant enzymes, including MT-1 and glutathione synthase, which was related to the activation of the Zn\(^{2+}\) sensor MTF-1 (5). Furthermore, the activity of antioxidant metalloenzymes was correspondingly increased, including S'e-GSHPx and Cu/Zn-SOD, as was the level of GSSG and TAC, a marker of overall tissue nonenzymatic antioxidants including vitamins A, C, and E. We speculate our findings congruently point to an activation of inherent compensatory mechanisms that strive to achieve a balance between pro- and antioxidant defenses at week 1 ALDOST, thus abrogating or even preventing cardiomyocyte necrosis, since scarring was not evident by light microscopy until week 4.

Furthermore, at week 4 ALDOST, and coincident with the delay in myocardial pathology [as reviewed elsewhere (66)], there was a marked rise in mitochondrial H\(_{2}\)O\(_{2}\) production and tissue levels of 8-isoprostane, in keeping with the unbridled rate of lipid peroxidation, reflecting a dysequilibrium between the rate of superoxide formation and matrix H\(_{2}\)O\(_{2}\) scavenging. This prooxidant state ensues in the absence of a proportional further increase in antioxidant defenses beyond that seen at week 1 suggesting that antioxidant defenses were temporarily overwhelmed, including GSHPx activity and TAC. This evolving dysequilibrium between prooxidants and antioxidant defenses ultimately led to oxidative stress-induced cardiomyocyte necrosis and subsequent tissue repair with scarring first seen at week 4. We believe Ca\(^{2+}\) overloaded mitochondria are the likely initial source of oxidative stress in these cells, which then perpetuate to involve their cytosol, where other sources of ROS could be contributory. This sequence of events needs to be examined in future studies using a mitochondrial-specific antioxidant (74) or a specific mitochondrial Ca\(^{2+}\) uptake inhibitor (27).

In this context, mitochondria serve as an endogenous Ca\(^{2+}\) buffer mechanism regulating intracellular free Ca\(^{2+}\) concentrations within a narrow physiological threshold. The Na\(^{+}\)-dependent mitochondrial uniporter of the inner membrane is dominant in the heart and sequesters Ca\(^{2+}\) when cytosolic Ca\(^{2+}\) levels rise severalfold above the resting concentrations and such overloading is prolonged (37). In chronic ALDOST, the early and persistent Ca\(^{2+}\) overloading of cardiac mitochondria, a major site of ROS generation, plays a key role in the genesis of mitochondrial pathology (24, 43). The mPTP is a regulated Ca\(^{2+}\)-dependent opening of the inner membrane transition pore that leads to a passive loss of membrane potential, ATP depletion, mitochondrial dysfunction with swelling and rupture of the outer membrane, and ultimately the necrosis of cardiomyocytes (41). Protecting mitochondria from oxidative stress-induced impairment offers an attractive and novel therapeutic approach. Unlike conventional antioxidants, which do not reach and penetrate these organelles, a mitochondria-specific antioxidant would provide a more targeted intervention (1, 34, 67, 74). An infiltration of inflammatory cells and myofibroblasts follows cardiomyocyte necrosis to restore the structural integrity of the myocardium with a replacement fibrosis or scarring. When ATP is available, the mPTP induces apoptosis, i.e., sterile cell death given an absence of inflammatory cells and fibroblast responses, where scarring is averted. We have not found evidence of apoptosis during ALDOST (unpublished observations), although others have and linked this to a concentration-dependent response to aldosterone (16). Cyclophilin D, an adenine nucleotide, regulates mPTP and necrotic cell death induced by intracellular Ca\(^{2+}\) overloading and H\(_{2}\)O\(_{2}\) overproduction (6, 55). CsA binds directly to cyclophilin D to inhibit its activity and thereby prevents mPTP opening and parenchymal cell necrosis (15). Whether cotreatment with CsA or a nonimmunosuppressive analog of CsA would prevent cardiomyocyte necrosis during ALDOST remains to be investigated. Indirect measures that would reduce the accumulation of ROS within mitochondria and, in turn, block mPTP opening include divalent cations (Mg\(^{2+}\) and Mn\(^{2+}\)) (42). In this context, the mechanism underlying the reported cardioprotective role of a Zn\(^{2+}\) supplement

![Fig. 7. Chronic aldosteronism involves the intrinsically coupled dyshomeostasis of Ca\(^{2+}\) and Zn\(^{2+}\) and includes cardiac myocytes and mitochondria that regulate the induction of oxidative stress and activation of endogenous antioxidant defenses. The accompanying intracellular Ca\(^{2+}\) overload, which occurs via l-type Ca\(^{2+}\) channels (LTCC) and is mediated by parathyroid hormone (PTH), accounts for a rise in intracellular Zn\(^{2+}\) to a lesser extent. The excessive accumulation of intracellular Ca\(^{2+}\) and induction of oxidative stress activate the expression of membrane-bound Zn\(^{2+}\) transporters, the major route of Zn\(^{2+}\) entry, and the release of Zn\(^{2+}\) from the Zn\(^{2+}\)-metallothionein (MT)-I complex. Collectively, increased intracellular Zn\(^{2+}\) contributes to antioxidant defenses. Persistent intracellular Ca\(^{2+}\) overloading, a result of chronic secondary hyperparathyroidism, accounts for the rate of oxidative stress exceeding (heavy line) antioxidant defenses. Cardiomyocyte necrosis with tissue repair and scarring are the end result.](http://ajpheart.physiology.org/10.1152/ajpheart.00373.2009)
in inhibiting mPTP opening needs to be further addressed, although the role of Zn$^{2+}$ in maintaining intracellular redox homeostasis is well-established (49).

We acknowledge several limitations of our present study, which we plan to address in the future. We did not use electron microscopy to monitor ultrastructural aberrations in mitochondria at 4-wk ALDOST nor did we examine the respiratory functions, such as oxidative phosphorylation or ATP synthetic activity of cardiac mitochondria. To address the role of mitochondrial H$_2$O$_2$ generation and the effect of cyclophilin D on Ca$^{2+}$-activated mPTP-mediated cardiomyocyte necrosis, we plan to use a small peptide-based antioxidant that localizes to the mitochondrial inner membrane or CsA as cotreatment, respectively. Finally, we did not account for the potential transmural heterogeneity of Ca$^{2+}$ channel population density across the myocardium or the heterogeneity of mitochondria found within the subsarcolemmal and interfibrillar spaces and their respective diversity in oxidative capacities (39, 48, 70).

Clinical correlates of our findings are severalfold. Elevation in serum PTH, the mediator of cardiomyocyte and mitochondrial EICA during aldosteronism (19, 24, 44), is present in patients hospitalized because of their symptoms and signs of CHF (4, 61). In outpatients with heart failure (reduced ejection fraction), serum PTH levels have recently been reported to be an independent predictor of the need for hospitalization for CHF (63). As demonstrated herein, EICA of aldosteronism is persistent and accompanied by a progressive rise in oxidative stress that overwhips antioxidant defenses leading to the opening of the mPTP with ensuing necrotic cell death. Microscopic scarring, a footprint of previous necrosis, is present throughout the right and left ventricular myocardium of the explanted failing human heart (8, 23). Such diffuse scarring of the myocardium suggests ongoing cardiomyocyte necrosis; apoptosis does not beget a fibrous tissue response. In this context, an elevation in serum troponins, biomarkers of cardiomyocyte necrosis, has been reported in patients hospitalized with CHF in the absence of an acute coronary event or significant renal dysfunction and is associated with increased in-hospital and overall cardiac mortality (40, 47, 58, 73).

In summary and as depicted in Fig. 7, chronic ALDOST in rats is accompanied by intrinsically coupled dyshomoeostasis of Ca$^{2+}$ and Zn$^{2+}$ in cardiac myocytes and mitochondria where they serve as pro- and antioxidants during its early preclinical (week 1) and pathological (week 4) stages, respectively. When endogenous antioxidant defenses are overwhelmed by oxidative stress, the resulting imbalance between pro- and antioxidants leads to cardiomyocyte necrosis and reparative fibrosis, eventuating in myocardial scarring. It is intriguing to postulate that this coupled dyshomoeostasis could be pharmacologically uncoupled in favor of Zn$^{2+}$ and antioxidant defenses, thus laying the foundation for novel cardioprotective strategies. Toward this end, a Zn$^{2+}$ supplement or Zn$^{2+}$ ionophore have each proven cardioprotective in the chronic stress models of ALDOST and streptozocin-induced diabetic cardiomyopathy, whereas the Zn$^{2+}$ ionophore has been effective in the acute stressor states associated with I/R injury and isoproterenol administration (18, 20, 26, 46, 71).

ACKNOWLEDGMENTS

We thank Richard A. Parkinson for editorial and statistical assistance and scientific illustrations.

GRANTS

This work was supported, in part, by NIH Grants R01-HL-73043 and R01-HL-90867 (K. T. Weber). Its contents are solely the opinion of the contributing authors and do not necessarily represent the official views of the NIH.

DISCLOSURES

The authors have no conflicts of interest to disclose.

REFERENCES

CALCIUM AND ZINC DYSHOMEOSTASIS


21. Corte ED, Stirpe F. The regulation of rat liver xanthine oxidase. Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme. Biochim Biophys Acta 26: 730–745, 1965.


